Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Retrieved on:
Monday, June 5, 2023
Biologics license application, Wesley Ira Purkey, Education, Progression-free survival, Hematology, Head, Aes, Survival, OS, Head and Neck Cancer Alliance, Vanderbilt University Medical Center, Sun, NSCLC, Cisplatin, Lung cancer, Assistant, Nasopharyngeal carcinoma, ASCO, Organization, CHRS, Incidence, Patient, Division, Annual general meeting, EFS, Diagnosis, NPC, PD-1, FDA, Death, BLA, Society, PD-L1, Support, Caregiver, Platinum, Pharmaceutical industry, Nursing, Sulfur, Typesetting, Medicine
REDWOOD CITY, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the final overall survival (OS) results of the JUPITER-02 study presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting. JUPITER-02 is a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with gemcitabine and cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
Key Points:
- JUPITER-02 is a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with gemcitabine and cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
- Median OS has not been reached in the toripalimab arm versus 33.7 months for chemotherapy treatment alone, HR=0.63 (95% CI 0.45-0.89); P=0.0083.
- No other PD-1 inhibitor currently approved in the U.S. has had a successful Phase 3 trial in recurrent or metastatic NPC that met its primary endpoints.
- Coherus projects potential approval in the third quarter of 2023 and plans to launch toripalimab in the United States directly, if approved.